The emerging role of alternative splicing in senescence and aging

Mathieu Deschénes and Benoit Chabot
Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec J1E 4K8, Canada

Summary
Deregulation of precursor mRNA splicing is associated with many illnesses and has been linked to age-related chronic diseases. Here we review recent progress documenting how defects in the machinery that performs intron removal and controls splice site selection contribute to cellular senescence and organismal aging. We discuss the functional association linking p53, IGF-1, SIRT1, and ING-1 splice variants with senescence and aging, and review a selection of splicing defects occurring in accelerated aging (progeria), vascular aging, and Alzheimer’s disease. Overall, it is becoming increasingly clear that changes in the activity of splicing factors and in the production of key splice variants can impact cellular senescence and the aging phenotype.

Key words: aging; alternative splicing; pre-mRNA; RNA; RNA binding proteins; senescence; splice variants; splicing.

Introduction
Aging is defined as a progressive decline of fitness over time, ultimately leading to death (Kirkwood & Holliday, 1979; Kirkwood, 2005). This decline is associated with several changes such as tissue deterioration and disorganization, organ dysfunction, and loss of stem cell renewal, the latter contributing to age-associated immunodeficiency. At the cellular and molecular levels, the aging phenotype varies between tissues but can include common hallmarks such as genomic and epigenetic instability, mitochondrial dysfunction, telomere attrition, and the accumulation of senescent cells (Kirkwood & Holliday, 1979; Kirkwood, 2005; López-Otín et al., 2013). Considered as one of the causes of age-related tissue degeneration, cellular senescence is an irreversible and programmed cell-cycle arrest that occurs in most diploid cell types (Hayflick & Moorhead, 1961). Senescence is associated with large-scale changes affecting a variety of processes such as cytokine secretion through the senescence-associated secretory phenotypes (SASPs), alterations in gene expression, and alternative splicing, as well as chromatin remodeling that includes senescence-associated heterochromatin foci (SAHF) (Narita et al., 2003; Rodier et al., 2009; Kuilman et al., 2010; Campisi, 2013; Holly et al., 2013). Senescence is also seen as a mechanism that prevents tumorigenesis (Serrano et al., 1997). The upregulation of tumor suppressors, such as p16INK4A, p21, and p53, as well as the activation of RB, is common in senescent cells, contributing to irreversible cell-cycle arrest (Beausejour, 2003; Sage et al., 2003; Kuilman et al., 2010; Campisi, 2013). Although replicative senescence is linked to telomere attrition (Alssopp et al., 1992; Bodnar et al., 1998), telomere shortening is not necessarily required for the onset of senescence, implying the existence of different senescence programs (van Deursen, 2014; Sharpless & Sherr, 2015). Consistent with this view, telomere-independent senescence can be controlled by pathways triggered by insults (stress-induced senescence), as well as by other intrinsic signals that occur during embryonic development and tissue repair (Von Zglinicki, 2002; Baker et al., 2008; Krizhanovsky et al., 2008; Schmidt et al., 2010; Nardella et al., 2011; Storer et al., 2013). Notably, senescence can also be engaged by the hyperactivation of factors, such as RAS, that promote cell growth, a process known as oncogene-induced senescence that may be linked to telomere dysfunction (Courtois-Cox et al., 2008; Gunes & Rudolph, 2012). While the exact connection between senescence and organismal aging is still much debated (Sharpless & Sherr, 2015), it has become increasingly clear that cellular senescence plays a role in some age-related diseases and in tissue degeneration associated with aging (Baker et al., 2008; Gunes & Rudolph, 2012; van Deursen, 2014). Senescent cells progressively accumulate in the tissues and organs of aging mammals including humans (Herbig et al., 2006; Ressler et al., 2006; Jeyapalan et al., 2007; Kreiling et al., 2011). This accumulation of senescent cells may be due in part to a decreased ability of the immune system at removing them (Nikolic-Zugich, 2008; Wang et al., 2011a). In addition, SASPs have been linked with aging organs and tissue degeneration (Parrinello et al., 2005; Coppé et al., 2008), where they are thought to enhance significantly the senescence of neighboring cells by a mechanism called paracrine senescence (Nelson et al., 2012; Acosta et al., 2013) (Fig. 1). Consistent with a role for senescence in aging, reducing the level of senescent cells is associated with a significant decrease in the incidence of age-related disorders (Baker et al., 2008, 2011; Zhu et al., 2015), and was shown recently to improve homeostasis and extend lifespan in mouse models (Baker et al., 2016; Baar et al., 2017). While nonreplicating cells in aging tissues such as muscle harbor senescent markers and can become senescent, they may, in general, be more resistant to senescence. However, muscle replicative stem cells and satellite cells likely undergo senescence and may contribute more importantly to aging. Altogether, the accumulation of senescent cells in tissues and organs suggests that this process contributes to the progressive deterioration that irremediably associates with aging (van Deursen, 2014).

As senescence and aging are characterized by global cellular and molecular changes, it is fair to expect that splicing control will also be subjected to alterations. The challenge is to determine whether these changes are collateral or direct effects, and how they contribute to senescence and aging. Several reviews have recently presented splicing defects linked to age-associated diseases, such as neurodegenerative disorders and cancer (Daguenet et al., 2015; Scotti & Swanson, 2015; Chabot & Shkreta, 2016). Here, our discussion will...
focus on recent progress achieved in documenting splicing alterations that directly contribute to cell senescence and aging, including accelerated aging (e.g., Hutchinson–Gilford progeria syndrome or HGPS).

**Basic concepts of alternative splicing**

The vast majority of precursor mRNAs (pre-mRNAs) produced by mammalian cells are made of exons separated by introns. Introns are normally removed leaving joined exons that form the mature mRNA. Splicing is carried out by the spliceosome, a massive complex that includes hundreds of proteins and five small nuclear ribonucleoproteins (snRNPs) named U1, U2, U4, U5, and U6 (Matera & Wang, 2014). The U1 and U2 snRNPs, respectively, recognize the 5' splice site and the branch site near the 3' splice site, making these two snRNPs important in defining intron borders. While many introns are removed constitutively, a large fraction of splicing signals are not always used leading to alternative splicing (Fig. 2). Alternative splicing occurs in transcripts produced by more than 95% of human genes (Pan et al., 2008; Wang et al., 2008), including ones implicated in senescence, apoptosis, and DNA repair (Schwerk & Schulze-Osthoff, 2005; Kelemen et al., 2013; Tang et al., 2013)

Alternative splicing is a complex and tightly regulated process. Many RNA binding proteins act as splicing regulators to facilitate or inhibit splice site recognition by spliceosome components (Fu & Ares, 2014). Splicing regulators include, but are not limited to, members of the hnRNP and SR families of proteins (Busch & Hertel, 2012; Giulietti et al., 2013). The combinatorial cooperation or antagonism between distinct RNA binding proteins is thought to play a major role in conferring specificity to splicing decisions (Fu & Ares, 2014). Their interactions and their cellular localization can be modulated by post-translational modifications (Howard & Sanford, 2015; Shkreta et al., 2016) that are often tightly integrated to environmental cues and homeostatic imbalances. Many splicing regulatory factors recognize short sequences within the pre-mRNA, and these elements can be classified in four groups termed Intronic and Exonic Splicing Silencers (ISS and ESS, respectively) and Intronic and Exonic Splicing Enhancers (ISE and ESE, respectively). The availability of these elements and of the splice sites will vary depending on the secondary structure adopted by the pre-mRNA (Jin et al., 2011).

The position of these elements relative to splicing signals is often critical to determine whether they will have a positive or negative impact on splicing. For example, a RBFOX binding site positioned downstream of a 5' splice site usually stimulates splicing, whereas the same site positioned in the upstream intron may promote exon skipping (Yeo et al., 2009) (Fig. 3).

In addition, the control of splice site selection is often coupled with transcription (Naftelberg et al., 2015). In this context, at least two mechanisms of control can exist. First, RNA polymerase II, transcription factors, and chromatin components can recruit generic and regulatory splicing factors. Second, change in the speed of transcription elongation and the presence of pausing sites linked to chromatin structure will affect the time given to splicing regulatory complexes to assemble and affect the use of a splice site in a competitive environment (Lee & Rio, 2015; Naftelberg et al., 2015; Nieto Moreno et al., 2015). One notable example of this coupling involves the DNA binding protein CTCF, which pauses the elongating polymerase to favor inclusion of exon 5 in the nascent CD45 pre-mRNA (Shukla et al., 2011). A developmentally induced DNA methylation event located in exon 5 inhibits the binding of CTCF to promote exon 5 skipping (Shukla et al., 2011).
It must also be pointed out that alternative splicing defects can arise when the levels of generic spliceosome components are altered. For example, the reduced expression of the protein SMN, that is implicated in snRNP assembly, leads to a wide-range of alternative splicing alterations (Zhang et al., 2008). Likewise, mutations in the snRNP components PRPF8, PRPF3, U2AF35, and SF3B1 cause diseases (e.g., retinitis pigmentosa for PRPF proteins, and myelodysplasia for U2AF35 and SF3B1) that are associated with broad changes in the production of splice variants (Chabot & Shkreta, 2016). Splicing defects may occur because splice site selection and spliceosome kinetics are highly dependent on the concentration of core spliceosomal components, and that alternative splicing units often harbor weaker splice sites that may be more sensitive to drops in the levels of generic splicing factors.

Aging and alternative splicing control

With such a complex regulatory machinery controlling splicing decisions, the molecular changes that occur with aging are therefore likely to impact the activity of factors that control splicing. A gene ontology analysis in both human and mouse reported that changes in pathways such as mRNA binding, RNA processing, and RNA splicing are strongly associated with age (Southworth et al., 2009; Harries et al., 2011). Age-related splicing changes in the human brain affect pathways such as sugar metabolism and DNA repair (Tollery et al., 2011), both relevant to aging (Colman et al., 2009; López-Otín et al., 2013).

It is estimated that more than 50% of all age-associated alterations in alternative splicing are due to changes in the expression of splicing factors (Mazin et al., 2013) (Table 1). Through microarray analysis, splicing changes have been linked to several splicing factors, including PTB (aka hnRNP I), ESRP1/ESRP2, NOVA1, and hnRNP K, whose expression also decreases with age (Tollervey et al., 2011). Recently, the expression of splicing regulators hnRNP A1 and A2 was linked positively to parental longevity in humans (Lee et al., 2016). Alterations in RBP expression may be caused by changes in the activity of transcription factors (Table 1). For instance, the activity of transcription factors such as STAT, IRF, GATA, and NF-kB is presumed to vary with age (Stilling et al., 2014). Moreover, transcription factors can themselves be subject to age-dependent alternative splicing that in turn may affect the expression of target genes. For example, microarray analysis showed that STAT1 splicing was significantly disrupted in aging human peripheral blood cells (Harries et al., 2011), although it is unclear whether STAT1 splice variants display differences in their ability to activate the expression of target genes.

In the worm Caenorhabditis elegans, the enhanced longevity elicited by caloric restriction is compromised by depleting SFA-1, which is the homolog of the mammalian splicing factor SF1, known to interact with the branchsite region (Heintz et al., 2016). Notably, overexpression of SFA-1 is sufficient to increase worm longevity. The depletion of SFA-1 preferentially promotes splicing defects in transcripts involved in metabolic processes including lipid catabolism and carbohydrate transport, and affects the activity of components of the TORC1 pathway (Heintz et al., 2016). Whether overexpression of SFA-1 corrected the noted splicing defects has not been investigated. An important component of the TORC1 pathway is mTOR whose alternative splicing is controlled by Sam68 (Huot et al., 2012). Although overexpression of the splice variant mTORC8 can promote tumorigenesis (Panasyuk et al., 2009), it is not known whether its production is affected during aging. However, ablation of Sam68 protects mice from age-related loss of bone mass (Richard et al., 2005).

Age-related splicing changes in mice can also be regulated in an unexpected manner. For instance, the age-dependent nuclear translocation of the ion channel subunit protein P2X6 in mouse allows it to interact with and sequester the U2 snRNP protein SF3A1, decreasing overall splicing activity (Díaz-Hernández et al., 2015). However, this phenomenon appears to saturate when mice reach adult age, suggesting that this process may be part of normal maturation and development rather than being associated with aging per se.

Most transcripts encoding splicing regulatory factors are themselves subject to alternative splicing. High-throughput analyses revealed that the splicing profiles of Hnrnph1, Hnnpol, Hnnpma1, Srsf5, Srsf6, and Srsf11 change through aging in mice, with human SRSF5 and SRSF1 being among the most altered by aging (Harries et al., 2011; Stilling et al., 2014). These changes in turn possibly alter the alternative splicing of numerous transcripts. Altogether, there is growing evidence documenting that the transcription and splicing of splicing regulators are altered in aging tissues. The accumulation of such alterations is likely to have a profound effect on the transcriptome of aging cells and the aging phenotype.

Age-related splicing alterations in growth regulators

Several genes produce transcripts whose alternative splicing changes in aging tissues or during prolonged cell passages in culture. An important question is whether those changes are the causes or the consequences of aging. Although recent studies have reported splicing changes in transcripts encoding proteins involved in processes that are intimately
associated with aging, such as DNA damage sensing, DNA repair, and telomere biogenesis (Tollervey et al., 2011; Rodríguez et al., 2016), we currently do not know if these switches produce splice variants with distinct functional properties. Here we will restrict our discussion to splice variants for which experimental evidence support a role in aging or senescence.

p53

One of the best known and possibly most important growth regulators is the tumor suppressor protein p53 that is implicated in cell-cycle arrest, senescence, and apoptosis (Vogelstein et al., 2000; Lowe et al., 2004). Mice lacking p53 develop normally but are highly predisposed to spontaneous tumor formation (Donehower et al., 1992). Most human cancers have a mutated p53 or express low level of wild-type p53 (Kamijo et al., 1998; Onel & Cordon-Cardo, 2004). The role of p53 in human aging is supported by epidemiological studies (van Heemst et al., 2005; Ørsted et al., 2007), and the fact that p53 regulates several processes relevant to organismal aging (Rufini et al., 2013); p53 can promote apoptosis, the DNA damage response, autophagy, and mitophagy (Eisenberg et al., 2009; Liang, 2010; Gao et al., 2011; Wang et al., 2011b; Tucci, 2012). Although p53 contributes to senescence-associated replicative arrest, it can restrain SASP (Coppé et al., 2008; Raj & Attardi, 2013).

The alternative splicing of p53 transcripts generates the truncated variant p44 that lacks the transactivation domain (Fig. 4a), and whose production increases in aging mice (Pehar et al., 2014). Notably, p44 can also be produced by an internal ribosome entry site (IRES) in the p53 mRNA. This mechanism occurs preferentially at the G1-S cell-cycle transition and is not inducible by stress (Courtois et al., 2002; Ray et al., 2006). The respective contribution of the splicing-mediated and the IRES-mediated processes to the production of p44 in aging cells is unclear. What is clear however is that overexpression of p44 in transgenic mice (p44+/−) leads to an accelerated age-associated phenotype, suppresses cell proliferation, and increases senescence (Maier et al., 2004) (Fig. 4b). These effects do not occur in p44 mice lacking p53, indicating that full-length p53 is necessary to elicit the aging phenotype (Maier et al., 2004). Notably, p47 (the human orthologue of p44) interacts with full-length p53 to modulate p53 activity (Courtois et al., 2002; Ghosh et al., 2004). Compared to the p53 homodimer, the p44/p53 complex displays distinct half-life, post-translational modifications, and promoter affinity (Camposi, 2004; Sc Rabale et al., 2005). Interestingly, the accelerated aging and growth arrest caused by disrupting the balance between p53 and p44 is functionally linked to the pathway initiated by the Insulin-like Growth Factor-1 (IGF-1) (Maier et al., 2004), which extends lifespan in C. elegans, D. melanogaster, and mice when inhibited. p53 modulates the IGF-1 pathway by decreasing the expression of the IGF-1 receptor (IGF-1R) (Werner et al., 1996). In contrast, mice overexpressing p44 display high levels of IGF-1/ IGF-1R (Pehar et al., 2010). Notably, the oncogenic MEK protein kinase has been associated with senescence when it is hyperactivated in a mouse model (Lin et al., 1998). Hyperactivation of the RAF-MEK-ERK pathway by high levels of IGF-1 induces cell-cycle arrest (Maier et al., 2004). This effect is considered a fail-safe mechanism that increases senescence, and it may explain at least in part the aging defect of p44+/− mice (Campisi, 2004; Maier et al., 2004). p44+/− transgenic mice also display premature synaptic deficit, cognitive decline as well as Alzheimer’s disease-like features, possibly associated with the abnormal phosphorylation of the microtubule-binding protein tau (Pehar et al., 2010). In fact, p44 is reported to bind, independently of p53, to the
promoter of several tau kinases genes resulting in their overexpression (Pehar et al., 2014). Thus, altering the balance between p53 variants can affect aging in mice (Campisi, 2004; Maier et al., 2004; Pehar et al., 2014), although it is unclear if the above conclusions apply to human aging.

In addition to p44, other p53 variants participate in the onset of senescence. In contrast to p53, whose level remained unchanged, the Δ133p53 and p53β splice variants (Fig. 4a) are, respectively, downregulated and upregulated in human senescent fibroblasts (Fujita et al., 2009). This functional link is supported by the fact that the knockdown of Δ133p53 induces robust senescent phenotypes, such as flattened morphology, an increase in β-galactosidase activity, and p21 overexpression. In contrast, upregulation of Δ133p53 induces cell proliferation, as well as repression of p21 and the E3 ubiquitin ligase MDM2 involved in p53 degradation; while expression of p53β has the opposite effects (Fujita et al., 2009). Overexpression either Δ133p53 or p53β in p53-null fibroblasts had no effect, indicating that these variants need to interact with full-length p53 to impact the senescent program (Fujita et al., 2009).

Despite clear differences in the function of p53 splice variants, little is known about what regulates their production by alternative splicing. The SR protein SRSF3 interacts with the p53 pre-mRNA (Tang et al., 2013) and downregulates the production of p53β (Tang et al., 2013). Moreover, senescent human fibroblasts and p53β overexpressing cells display reduced levels of SRSF3 mRNA. A drop in SRSF3 is not seen in oncogenic RAS-induced senescence, suggesting that the role of SRSF3 is specific to replicative senescence. The knockdown of SRSF3 also induces a senescent phenotype, p53 phosphorylation and an increase in p53β (Tang et al., 2013). These findings suggest a crucial role for SRSF3 in preventing senescence, but additional analyses in tissues are needed to confirm whether this observation is relevant to normal aging.

**IGF-1**

While IGF-1 is expressed in nearly every tissue, it is mostly produced by the liver, from which it enters the general circulation (Flier et al., 1997; Sjögren et al., 1999). IGF-1 is an important player in normal growth and development. Mutations that reduce IGF-1 signaling increase the lifespan of *D. melanogaster* and *C. elegans* (Altintas et al., 2016). Caloric restriction, a condition that increases longevity in several organisms, promotes a drop in IGF-1 synthesis and signaling (Sjögren et al., 1999; Campisi, 2004; Tucci, 2012; Higashi et al., 2014). The IGF-1 transcript undergoes alternative splicing to produce at least three mRNA variants: IGF-1Ea is the most abundant variant lacking exon 5; IGF-1Eb is only found in humans and lacks exon 6; and IGF-1Ec, also known as the Mechano Growth Factor (MGF), contains both exons 5 and 6, and is associated with satellite cell activation, proliferation, and skeletal muscle repair (Yang & Goldspink, 2002; Goldspink, 2005). Exon 5 of IGF-1 contains a regulatory ESE that recruits SRSF1 to promote exon 5 inclusion (Smith et al., 2002).

The splicing variants IGF-1Ea and MGF affect different pathways. IGF-1Ea through its receptor IGF-1R activates both the RAF-MEK-ERK and the

---

**Table 1** Age-related alteration of notable transcription (in bold) and splicing factors

| Genes | Function | Age-related alteration | Direction | Notes | References |
|-------|----------|-----------------------|-----------|-------|------------|
| Ap1   | Transcription | Expression of target genes | Up | Mice | Stilling et al. (2014) |
| EfnuG2| Splicing | Alternative splicing | N/A | Mice | Rodríguez et al. (2016) |
| ESRP1 | Splicing | Expression | Up | Human | Tollervey et al. (2011) |
| ESRP2 | Splicing | Expression | Up | Human | Tollervey et al. (2011) |
| Ets   | Transcription | Expression of target genes | Up | Mice | Stilling et al. (2014) |
| Gata  | Transcription | Expression of target genes | Up | Mice | Stilling et al. (2014) |
| HnrrnP1| Splicing | Alternative splicing | N/A | Mice | Stilling et al. (2014) |
| HnrrnP2| Splicing | Alternative splicing | N/A | Mice | Stilling et al. (2014) |
| HNRRPK| Splicing | Expression | Down | Human | Tollervey et al. (2011) |
| HnrnpA1| Splicing | Alternative splicing | N/A | Mice | Stilling et al. (2014) |
| HnrnpB1| Splicing | Expression, expression of target genes | Up | Mice | Stilling et al. (2014) |
| NOVA1 | Splicing | Expression | Down | Human | Tollervey et al. (2011) |
| PpIF3 | Splicing | Alternative splicing | N/A | Mice | Rodríguez et al. (2016) |
| PpIF8 | Splicing | Alternative splicing | N/A | Mice | Rodríguez et al. (2016) |
| PTBP1 | Splicing | Expression | Up | Human | Tollervey et al. (2011) |
| PTBP2 | Splicing | Expression | Down | Human | Tollervey et al. (2011) |
| RBFOX1| Splicing | Expression | Down | Human | Tollervey et al. (2011) |
| SFB1 | Splicing | Alternative splicing | N/A | Mice | Rodríguez et al. (2016) |
| SNU7 | Splicing | Expression | Down | Human | Tollervey et al. (2011) |
| SNPRB2| Splicing | Expression, expression of target genes | Up | Mice | Stilling et al. (2014) |
| SRSF1 | Splicing | Alternative splicing | N/A | Human and mice | Stilling et al. (2014); Harries et al. (2011) |
| Srsf11 | Splicing | Alternative splicing | N/A | Mice | Stilling et al. (2014) |
| SRSF2 | Splicing | Expression | Down | Human | Tollervey et al. (2011) |
| Srsf5 | Splicing | Alternative splicing | N/A | Mice | Stilling et al. (2014) |
| RSF6 | Splicing | Alternative splicing | N/A | Human and mice | Stilling et al. (2014); Harries et al. (2011) |

**STATs**

| Genes | Function | Age-related alteration | Direction | Notes | References |
|-------|----------|-----------------------|-----------|-------|------------|
| STATs | Transcription | Alternative splicing, expression, expression of target genes | Up | Human and mice | Stilling et al. (2014); Harries et al. (2011) |
PI3K-AKT pathways that are respectively associated with proliferation and differentiation (Coolican et al., 1997; Stavropoulou et al., 2009). MGF activates in an IGF-1R-independent manner the RAF-MEK-ERK pathway only, supporting its role in proliferation and skeletal muscle repair (Philippou et al., 2009; Stavropoulou et al., 2009).

Early studies on IGF-1 splice variants revealed that their relative production did not significantly change with age. However, in contrast to IGF-1Ea, MGF levels are significantly induced after exercise in young compared to older rats, as well as in humans (Owino et al., 2001; Hameed et al., 2003). Based on these results, it was suggested that the age-associated decline in skeletal muscle repair and maintenance (Brooks & Faulkner, 1990) may be related to a progressive loss of MGF production after exercise.

**SIRT1**

The sirtuin SIRT1 is the mammalian orthologue of yeast sir2 and is an NAD+-dependent histone deacetylase (HDAC). SIRT1 has important functions in gametogenesis, embryonic development, skeletal muscle differentiation, and homeostasis (Cheng et al., 2003; Fulco et al., 2003; McBurney et al., 2003; Feige & Johan, 2008). SIRT1 also regulates inflammation by interfering with the NF-κB pathway (Salminen et al., 2008; Shinozaki et al., 2014) and represses p53 activity to reduce apoptosis during stress (Luo et al., 2001; Cheng et al., 2003).

Sir2/SIRT1 activation extends lifespan in yeast, C. elegans, Drosophila, as well as in mice (Kaeberlein et al., 1999; Tissenbaum & Guarente, 2001; Whitaker et al., 2013; Mitchell et al., 2014). Although sirtuins are considered anti-aging proteins (Guarente, 2007), the role of SIRT1 in human aging remains controversial (Ledford, 2011; Lombard et al., 2011). For instance, while resveratrol stimulates the interaction between SIRT1 and lamin A, whose importance in aging defects is well documented (Liu et al., 2012), activation of SIRT1 by resveratrol has no demonstrated impact on health or longevity (Semba et al., 2014). In mammals, the activation of SIRT1 reduces the level of circulating IGF-1, also consistent with the caloric restriction model (Brown et al., 2010).

Sir2 can activate autophagy (Morselli et al., 2010) and may enhance longevity by producing more homogeneously healthy mitochondria (Nemoto et al., 2005). It has been proposed that the drop in NAD+ level that occurs in aging tissues (Braidy et al., 2011; Massudi et al., 2012) decreases the activity of SIRT1 leading to a progressive accumulation of

---

**Fig. 4** p53 splice variants and aging. (a) p53 alternative splicing and the production of splice variants. The structure of the p53 gene is illustrated with exons and introns, alternative start sites of transcription (P1 and P2 arrows), and translation initiation codons (ATG). p44 is produced when intron i2 is retained, eliciting the use of a downstream initiation codon in exon 4. The use of the alternative start site (P2) leads to the production of the Δ133p53 isoform. Complex alternative splicing can occur within intron 9 to produce β or γ (α is indicated here as the simplest case where the whole intron is removed). Both p44 and Δ133p53 lack the transactivation domain. (b) p44 forms a complex with p53 to regulate its activity. When overexpressed, p44 leads to senescence and hyperactivates the IGF-1 pathway that in turn promotes cell-cycle arrest through the RAF-MEK-ERK pathway. p44 is also linked to age-related cognitive decline as its overexpression upregulates tau kinases. Variants p53β and Δ133p53 also regulate senescence by, respectively, activating and inhibiting the cell-cycle arresting protein p21.
SIRT1 undergoes alternative splicing of exon 8 to produce SIRT1Δ8 which lacks a portion of the deacetylase domain. SIRT1Δ8 expression rises after stresses, and while this variant by itself displays reduced p53 deacetylation activity, it exerts an additive deacetylation effect on p53 when expressed with full-length SIRT1 (Lynch et al., 2010). Combining stresses with the depletion of p53 also leads to an overexpression of SIRT1Δ8 mRNA and protein, while activating p53 has the opposite effect (Lynch et al., 2010). In stress conditions, the depletion of SIRT1Δ8 leads to an abnormal accumulation of p53, accompanied by a significant increase in apoptosis, consistent with a repressive role for SIRT1Δ8 in p53 regulation after stress (Lynch et al., 2010).

A stress-induced drop in the expression of SRSF2 has been implicated in the production of the SIRT1Δ8 variant (Lynch et al., 2010). SIRT1 splicing implicates RNA binding proteins that are also linked to p53 activity. Overexpression of RNA binding proteins TIA1 or TIAL1 promotes SIRT1 exon 8 inclusion and inhibits cell growth (Zhang et al., 2014), while their knockdown has the opposite effect. A gene ontology analysis reveals that the tumor suppressor phenotype triggered by TIA1/TIAL1 overexpression involves the upregulation of p53 targets (Sánchez-Jiménez et al., 2015). Conversely, the RNA binding protein HuR, which enhances p53 mRNA translation by binding to its 3‘ UTR (Mazan-Mamczarz et al., 2003; Abdelmohsen et al., 2014), also promotes SIRT1 exon 8 skipping when overexpressed, while the opposite effect is observed following HuR knockdown (Zhang et al., 2014). Taken together, the p53-dependent alternative splicing of SIRT1 exon 8 and the reciprocal regulatory relationship with p53 suggest a negative feedback loop (Lynch et al., 2010) (Fig. 5) that may be important to prevent abnormal cell growth. Notably, both suboptimal and excess levels of SIRT1 have a tumor suppressive impact in rodents (Firestein et al., 2006; Coles et al., 2006; Vieyra et al., 2002). The level of ING1a increases at the expense of ING1b when cells approach senescence, suggesting a role for ING1a in cell-cycle arrest (Soliman et al., 2008). Consistent with this view, cells overexpressing ING1a display senescence phenotypes such as formation of SAHF, flat morphology, and expression of senescence-associated β-galactosidase and p16 (Soliman et al., 2008). While ING1b also participates in senescence through upregulation of p16 (Li et al., 2011), it sensitizes young cells to apoptosis (Scott et al., 2001; Vieyra et al., 2002b; Guérillon et al., 2013) (Fig. 6). ING1b-mediated apoptosis may occur by stabilization of p53, possibly by inhibiting deacetylation mediated by SIRT1 (Vaziri et al., 2001; Kataoka et al., 2003; Binda et al., 2008; Guérillon et al., 2013). The splicing shift toward ING1a may help to maintain the senescence status and thus may prevent apoptosis. Overall, the fact that splice variants of p53 or ING1 can differentially trigger senescence in vitro or age-related phenotypes in vivo suggests that their alternative splicing control is directly implicated in aging.

### Alternative splicing and age-related diseases

A number of human diseases known as progeroid syndromes provoke phenotypic alterations that resemble those noted during normal aging. These include Hutchinson–Gilford Progeria syndrome (HGPS or progeria), Werner syndrome, and Cockayne syndrome. The study of HGPS has revealed that alternative splicing defects are responsible for some of its distinctive features.

### Progeria

Progeria or HGPS is defined by a premature aging phenotype associated with a high incidence of age-related disorders, such as cardiovascular impairment and atherosclerosis (Merideth et al., 2008; Hisama et al., 2011). Premature cell senescence has also been reported, consistent with the notion that senescence is associated with aging (Huang et al., 2005). While the relationship between HGPS and normal physiological aging is still debated (Burtner & Kennedy, 2010), tissues from HGPS patients are considered a good model for research on vascular aging as HGPS shares common mechanisms with age-related vascular dysfunction (Brassard et al., 2016). Lamin proteins are components of the nuclear lamina and play key roles in nuclear structure and in processes such as transcription and DNA replication (Goldman et al., 2002; Dechat et al., 2008, 2009). Lamin A interacts with and activates SIRT1 (Liu et al., 2012). The LMAA gene normally encodes both lamin A and C proteins. A silent C to T mutation in exon 11 has been implicated in the most common form of HGPS (Hutchison, 2002; Eriksson et al., 2003). The mutation increases by 50-fold the use of an alternative 5‘ splice site situated 5 nucleotides upstream of the mutation, producing a variant lacking 150 nucleotides and a truncated protein called progerin lacking the corresponding 50 amino acids (Fig. 7). Progerin is abnormally processed and becomes sequestered in the nuclear membrane, decreasing the acetylation activity of SIRT1. Notably, progerin is detected in trace amounts in healthy tissues that lack the mutation. This observation and the fact that progerin is also produced in other animals (Lopez-Mejia et al., 2011) suggest that progerin may have a normal physiological function (Hutchison, 2002; De Sandre-Giovannoli et al., 2003; Eriksson et al., 2003; Scaffidi & Misteli, 2006; Liu et al., 2012). Lamins, including progerin, may regulate senescence pathways in patients with HGPS and healthy individuals (Karlsted, 2002; Freund et al., 2012; Wood et al., 2014). Notably, physical insults like UVA, but not UVB, drastically change the splicing profile of normal LMNA to favor the production of progerin in cultured human fibroblasts (Ikehata & Ono, 2011; Takeuchi & Rünger, 2013). In contrast to UVB, which preferentially produce pyrimidine dimers, the indirect generation of oxidative DNA damage through ROS induction by UVA (Cadet et al., 2009) may explain the upregulation of progerin. Thus, the UVA-induced increase in progerin production may accelerate skin aging (Takeuchi & Rünger, 2013). It has also been noted that the production of progerin in an HGPS mouse model associates with impaired developmental splicing and an altered production of splice variants in the skin (Rodríguez et al., 2016).

Although the mRNA level of progerin does not significantly increase in aging biopsies (Scaffidi & Misteli, 2006; Rodríguez et al., 2009; Cao et al., 2011), the accumulation of progerin in the nuclear membrane, as reported in HGPS and healthy tissues, is believed to contribute to...
Senescence. Consistent with this view, ectopic expression of progerin can induce progeroid phenotypes, such as nuclear misshape, premature senescence (Candelario et al., 2006), and telomere aggregation and dysfunction independently of telomere attrition (Benson et al., 2010; Cao et al., 2011). Also, the depletion of progerin downregulates expression of p21, as well as that of growth regulators IGFBP3 and GADD45B (Varela et al., 2005; Scaffidi & Misteli, 2006). Moreover, shortened telomeres induce the production of progerin, suggesting a positive feedback loop that ultimately converges into activation of senescence in normal tissues (Cao et al., 2011).

The above results suggest that the abnormal accumulation of progerin contributes to senescence and accelerated aging. As this accumulation also occurs during the normal aging process, the same senescence pathway may be activated in healthy individuals (Scaffidi & Misteli, 2006; McClintock et al., 2007). Despite several aging phenotypes displayed by patients with HGPS, an increase in the incidence of cancer is not one of them (Hennekam, 2006; Coppede & Migliore, 2010). Based on these observations, it is tempting to suggest that progerin, while protecting the organism from tumorigenesis, accelerates the accumulation of senescence leading to degenerative phenotypes. Notably, patients with HGPS also do not show any increase in the incidence of Alzheimer’s disease, potentially providing insight into protective mechanisms (Nelson et al., 2011).

The splicing regulatory proteins SRSF1 and SRSF6 bind close to the progerin-producing splice site and elicit mutually antagonistic effects in both HeLa cells and primary HGPS fibroblasts; SRSF6 decreases the use of the progerin-specific 5’ splice site, while SRSF1 enhances it (Lopez-Mejia et al., 2011). Consistent with this result, the depletion of SRSF6 increases progerin accumulation in the nucleus of HGPS fibroblasts, while depletion of SRSF1 reduces the level of progerin and nuclear misshape (Lopez-Mejia et al., 2011). Notably, the C to T mutation in exon 11 of LMNA increases the accessibility of the progerin 5’ splice site, which is normally sequestered in a conserved duplex structure (Lopez-Mejia et al., 2011).

Vascular aging

Vascular aging is characterized by a decline of endothelial function leading to a progressive deficiency in cardiovascular repair mechanisms (Ribera-Casado, 1999) and vascular walls remodeling (Brandes et al., 2005; Minamino & Komuro, 2007). The decreasing proliferative potential of endothelial cells and the accumulation of senescent cells also deleteriously affect angiogenesis, nutrient trafficking, homeostasis, and the response to TGF-β (Dimri et al., 1995; Foreman & Tang, 2003). Alternative splicing plays a crucial role in vascular integrity, and defective splicing leads to cardiovascular diseases such as aortic aneurysm and arrhythmias (Martin et al., 2014; Dlamini et al., 2015; Rizzacasa et al., 2017). For instance, the proportion of titin splice variants, which contribute to cardiac myocytes stiffness, is altered in heart diseases (LeWinter & Granzier, 2013). Alternative splicing of the titin transcript is controlled by RBM20, which acts on other pre-mRNAs whose splicing is linked to dilated cardiomyopathy and other vascular diseases (Guo et al., 2012; Li et al., 2013; Maatz et al., 2014). Splicing regulators like hnRNP A1 and PTBP1 also contribute to cardiovascular risk factors including the metabolism of cholesterol, omega-3, and omega-6 (Medina et al., 2011; Mozaffarian & Wu, 2011; Reardon et al., 2011; Yu et al., 2014). Given that aging is a risk factor to vascular diseases, it is likely that age-dependent alterations in at least some of the above splicing events and regulators contribute to cardiovascular diseases.

References

Candelario et al., 2006
Cao et al., 2011
Dlamini et al., 2015
LeWinter & Granzier, 2013
Martin et al., 2014
Medina et al., 2011
Mozaffarian & Wu, 2011
Reardon et al., 2011
Yu et al., 2014

© 2017 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
One example of age-related splicing change in the vascular context concerns the ENG gene which codes for the glycoprotein endoglin, a transmembrane co-receptor of TGF-β that functions in endothelial cell growth, angiogenesis, differentiation, and senescence. The TGF-β receptor complex includes endoglin and the TGF-β type I and II receptors. The type I receptor associates with two antagonistic proteins, ALK1 and ALK5, that regulate the signal induced by TGF-β (Bernabeu et al., 2007; ten Dijke & Arthur, 2007). The ENG pre-mRNA is alternatively spliced to produce at least two mRNA variants: the long (L) and the short (S) version. The S variant has a retained intron that provides a premature stop codon before the last exon (Bellón et al., 1993; Pérez-Gómez et al., 2005). While L-endoglin is predominantly produced in young vascular endothelial cells, a shift toward the S form occurs during normal aging, as well as at in late passages in cell culture (Blanco et al., 2008; Blanco & Bernabeu, 2011). S-endoglin is more likely to interact with ALK5 than ALK1, whereas L-endoglin has more affinity for ALK1. Thus, the cellular responses mediated by TGF-β signaling may depend on the alternative splicing of endoglin as the levels of ALK1 and ALK5 do not significantly change during senescence (ten Dijke & Arthur, 2007). L-endoglin has a proliferative and proangiogenic effect on endothelial cells through its interaction with ALK1, while S-endoglin is more likely to induce a senescence phenotype (Lebrin et al., 2004; Düwel et al., 2006). Endothelial cells of transgenic mice overexpressing S-endoglin show a lower proliferative rate, suggesting that S-endoglin may contribute to senescence and age-associated vascular pathologies (Blanco et al., 2008).

SRSF1 has been implicated in regulating the production of S- and L-endoglin variants. Overexpressing SRSF1 increases S-endoglin mRNA, possibly by interfering with branch site usage to promote intron 2 retention in ENG transcripts (Blanco & Bernabeu, 2011).

Alzheimer's disease (AD)

Among age-related disorders, AD is characterized by progressive neurodegenerative phenotypes leading to memory loss and dementia (Burns & Iliffe, 2009), possibly caused by aggregation of amyloid beta (Aβ) in the brain (Zheng & Koo, 2011; Kandalepas & Vassar, 2014). Aβ is the product of two subsequent enzymatic digestions driven, respectively, by the β-secretase (BACE) and the γ-secretase; the initial substrate for these enzymes is the amyloid precursor protein (APP) (Citron et al., 1995; Koffie et al., 2011; Zheng & Koo, 2011; Chami & Checler, 2012; Kandalepas & Vassar, 2014). BACE turns out to be a more desirable target against AD as γ-secretase is believed to be more critical for normal function (Mowrer & Wolfe, 2008). The complex alternative splicing profile of BACE exons 3 and 4 generates at least four splice variants: I-501, I-476, I-457, and I-432 (Mowrer & Wolfe, 2008; Fisette et al., 2012). While total level of BACE transcripts remains unchanged when comparing young and old mice, the level of full-length I-501 increases in an age-dependent manner (Zohar et al., 2005). Considering the strong correlation between BACE activity and Aβ accumulation in the brain (Hsiao et al., 1996; Tanahashi & Tabira, 2001), a rise in BACE level and the consequent accumulation of Aβ may increase the predisposition to AD as well as to other age-associated cognitive impairments.

In addition, age-related expression and splicing changes have been noted both in BACE and APP in the mice hippocampus (Stilling et al., 2014). Interestingly, overexpression of APP in AD mice model alters BACE alternative splicing in the brain, suggesting a feedback role for APP on Aβ production through BACE splicing (Zohar et al., 2005).

Little is known about the control of alternative splicing of BACE1 transcripts. An ESE potentially recognized by SRSF2 positively regulates the inclusion of exon 4 (Mowrer & Wolfe, 2009). The exon 3 and exon 4 contain several alternative splice sites leading to a complex splicing profile whose regulation is not understood. Notably, a G-rich sequence within exon 3 controls 5’ splice site selection to enhance production of the full-length mRNA. This G-rich sequence forms a G-quadruplex structure that interacts with the splicing factor hnRNP H (Fisette et al., 2012). Decreasing the level of hnRNP H by RNA interference significantly reduces production of full-length BACE, hence decreasing Aβ production (Zheng & Koo, 2011; Chami & Checler, 2012; Fisette et al., 2012). These findings identify potential targets for therapies that may help reduce the damaging effects of the Aβ accumulation in the brain observed in AD and normal aging, and show the essential role that alternative splicing and its regulation play in such diseases. It is worth restating that patients...
with HGPS are largely spared from Alzheimer’s disease and that they may represent a unique cohort to study the underlying protective mechanisms.

Conclusions and perspectives

Given the challenges associated with maintaining homeostasis in cells and tissues subjected to constant internal and external insults, we can anticipate that a subset of mutations and epigenetic changes may alter the expression or activity of spliceosome components and splicing regulatory factors. These changes may, in turn, alter the splicing profile in several transcripts, resulting in a cascade of alterations that may either activate senescence, promote apoptosis, or elicit tumor formation. Although senescence and apoptosis may protect against tumor formation, the gradual accumulation of senescent cells will elicit tissue degeneration and organ dysfunction. While progressive age-related disturbances in homeostasis do indeed correlate with a broad range of alterations in alternative splicing, the current challenge is to determine whether a specific splicing change contributes to the aging phenotype or is simply a consequence with little or no functional impact. In this review, we have focused on altered alternative splicing events whose contributions to age-related phenotypes are experimentally supported. These events occur in genes known for their implication in mechanisms that are relevant to cell senescence and organismal aging. Although we reviewed the impact of selected splice variants on aging, regulatory networks likely coordinate the production of splice variants from different genes to maximize functional outcomes that determine cell fate, and ultimately the aging phenotype. Consistent with this proposition, the activity of p53 in senescence and apoptosis can be modulated by SIRT1 and ING1, in turn affecting ING1 signaling and SIRT1 activity. Extending these relationships to the full repertoire of splice variants for all the components of the extended p53 regulatory network may be required to determine how important is the level of coordination and feedback involved in the production of splice variants contributing to aging. Already, the splicing regulatory proteins SRSF1, SRSF2, SRSF3, and SRSF6 are emerging as central players coordinating multiple splicing decisions in age-relevant and senescent transcripts (Fig. 8). Future studies will likely investigate in more details how defects in the expression or activity of these proteins, as well as hnRNP proteins and core spliceosomal components, affect senescence and aging. Another group of potentially relevant regulatory molecules are noncoding RNAs. Some display age-dependent changes in expression (e.g., see Gruner et al., 2016), and recent studies have implicated microRNAs, large noncoding RNAs, and circular RNAs in senescence and SASP (Abdelmohsen & Gorospe, 2015; Panda et al., 2017a). Specifically, the circular RNA CircPVT1, whose

Fig. 8 Contribution of SR proteins to senescence and the aging phenotype. As indicated, SRSF1, SRSF2, SRSF3, and SRSF6 enhance or repress the production of specific splice variants implicated in age-related phenotype, aging, and senescence.

Fig. 9 A model that links telomere function with splicing control. Telomere erosion would abrogate TPE-OLD to alter the expression/activity of splicing regulators such as SRSF2, in turn promoting a cascade of splicing alterations to affect the maintenance of genomic, chromatin, and telomere integrity (see text for details).
expression is reduced in senescent cells, is produced by circularization of an exon of the PVT gene through RNA splicing. CircPVT sequesters let-7 RNA and its depletion triggers senescence (Panda et al., 2017b). There is clearly a need to investigate further how splicing regulation is altered to affect the production of circular RNA molecules during senescence and aging. To help clarify the contribution of an expanding list of splice variants and regulators associated with aging, it would be useful to combine expression assays with the monitoring of phenotypes like cell growth and the production of senescent markers. Likewise, it would be informative to determine whether and how SAMP components produced by senescent cells reprogram the splicing profiles of neighboring cells.

While alterations in alternative splicing are likely contributing to aging, it is unclear what events initially trigger the change in activity of splicing regulators. Relevant to this question are recent studies in human cells that have uncovered links between telomere function and gene expression. Specifically, chromosome looping allows long telomeres to extend their effect on transcription as far as 10 Mb, a process termed Telomere Position-Effect On Long Distance (TPE-OLD) (Robin et al., 2014). As telomeres shorten during aging, TPE-OLD regulation becomes compromised, directly altering gene expression (Robin et al., 2015). If the looped-out chromosome portions host genes encoding splicing regulators or factors that control their activity, the loss of TPE-OLD may have a global impact on alternative splicing. A link between telomere function and the activity of splicing factors is supported by the observation that telomere dysfunction promotes the production of the LMNA splice variant progerin, which elicits senescence (Cao et al., 2011). In addition, mouse hematopoietic progenitor cells from telomerase-deficient mice have reduced levels of U2AF2, SF3B1, and SRSF2 (Colla et al., 2015). Moreover, telomerase-deficient and SRSF2-deficient mice share defects in the splicing of transcripts encoding components involved in DNA repair, chromatin structure, and telomere maintenance (Colla et al., 2015). These observations can be integrated into a model whereby TPE-OLD would be important for the activity of splicing factors such as SRSF2 (Fig. 9). Notably, the human and mouse Srsf2 and U2af2 genes are located less than 10 Mb from the telomeres on their respective chromosomes. In young cells, optimal telomere function would insure optimal SRSF2 expression, allowing correct splicing of transcripts encoding telomere maintenance, DNA repair, and chromatin factors. In cells of aging animals however, telomere erosion would lead to a disruption of TPE-OLD and decreased levels of SRSF2 that would elicit aberrant splicing of components required for genome integrity. It is also notable that age-related splicing changes occur in the same categories of transcripts that are affected by DNA damaging agents (i.e., DNA repair, chromatin, and RNA splicing) (Southworth et al., 2009; Harries et al., 2011; Tolllerev et al., 2011; Shkreta & Chabot, 2015).

While short telomeres not engaged in TPE-OLD may activate the DDR, whereby TPE-OLD would be important for the activity of splicing factors such as ApoER2 and SRSF2, ApoER2 splicing improved synaptic function, learning, and memory (Hinrich et al., 2016). Alternatively, given that a large collection of apoptotic regulators produce functionally antagonistic splice variants, and that the apoptotic pathway is repressed in senescent cells (Wang, 1995), SSOs may serve to encourage the production of pro-death variants in senescent cells to favor their elimination and thus prevent their deleterious contribution to aging tissues. Other anti-aging tools may emerge from the screening of small molecules capable of modulating splicing (Salton & Misteli, 2016). Compounds targeting generic splicing factors, such as SF3B1, may find a use as anticancer agents. As compounds that control the activity of SRSF proteins are being identified (Shkreta et al., 2017; Sigala et al., 2017), their pro-apoptotic or anti-senescent activities will need to be investigated. Overall, while additional links between splicing and different facets of aging will continue to be uncovered, compounds that can modulate specific splicing events or relevant splicing programs may offer innovative approaches to correct or postpone age-related disorders.

Acknowledgments
We thank L. Shkreta and M. Sohail for comments on the manuscript.

Funding
The work in the laboratory of BC is supported by the Canadian Institutes of Health Research (grant MOP-136948). BC is the Pierre C. Fournier Chair in Functional Genomics.

Conflict of interest
None declared.

References
Abad M, Moreno A, Palacios A, Narita M, Blanco F, Moreno-Bueno G, Narita M, Palmero I (2011) The tumor suppressor ING1 contributes to epigenetic control of cellular senescence. Aging Cell 10, 158–171.
Abdelmohsen K, Gorospe M (2015) Noncoding RNA control of cellular senescence. Wiley Interdiscip. Rev. RNA 6, 615–629.
Abdelmohsen K, Panda AC, Kang MJ, Guo R, Kim J, Grammatikakis I, Yoon I-H, Dudekula DB, Noh JH, Yang X, Martindale JL, Gorospe M (2014) 7SL RNA represses p53 translation by competing with HuR. Nucleic Acids Res. 42, 10099–10111.
Acosta JC, Banito A, Wuestefeld T, Georglis A, Janich P, Morton JP, Athineos D, Kang T-W, Lasitschka F, Andrulis M, Pascual G, Morris KJ, Khan S, Jin H, Dharmalingam G, Snijders AP, Carroll T, Capper D, Pritchard C, Inman GI, Longerich T, Sansom OJ, Benitah SA, Zender L, Gil J (2013) A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol. 15, 978–990.
Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, Greider CW, Harley CB (1992) Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl Acad. Sci. USA 89, 10114–10118.
Altintas O, Park S, Lee S-P (2016) The role of insulin/IGF-1 signaling in the longevity of model invertebrates, C. elegans and D. melanogaster. BMB Rep. 49, 81–92.
Baar MP, Brandt RMC, Putatuv DA, Klein JDD, Derks KJW, Bourgeois BRM, Stryeek S, Rijken Y, van Willigenburg H, Feijtel DA, van der Pluijm I, Essers J, van Cappellen WA, van IJcken WF, Hoitsmuller AB, Pothof J, de Bruin RWF, Madl T, Hoeijmakers JHU, Campisi J, de Keizer PJL (2017) Targeted apoptosis of...
senescent cells restores tissue homeostasis in response to chemotaxis and aging. Cell 169, 132–147.e16.

Baker DJ, Perez-Terzic C, Jin F, Patel K, Niederländer NJ, Jeganathan K, Yamada S, Reyes S, Rowe L, Hidding HJ, Eberhardt NL, Terzic A, van Deursen JM (2008) Opposing roles for p16ink4a and p19Arf in senescence and aging caused by Bub1 insufficiency. Nat. Cell Biol. 10, 825–836.

Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, Wijers ME, Sieben CJ, Zhong JA, Saltness R, Borden AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JY (2013) Aging, cellular senescence, and cancer. EMBO J. 32, 201–204.

Colla S, Ong DST, Ogut I, Marchesi M, Mistry NA, Clise-Dwyer K, Ang SA, Sotti P, Viale A, Galban R, Skaarda K, Ganan Gomez I, Bristow CA, Estacio M, Weksberg DC, Ho YW, Hu B, Genovese G, Pettazzoni P, Maltasi A, Jiang S, Sui X, Ryan MC, Carugo A, Nezi L, Wei Y, Yang H, D’Anca M, Zhang L, Gaddis S, Gong T, Horner JW, Heffernan TP, Jones P, Cooper LN, Liang H, Kantarjian H, Wang YA, Chin L, Bueso-Ramos C, Garcia-Manero G, DeFillipo RA (2015) Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell 27, 464–677.

Bronte S, Anderson RA, Johnson SC, Kastman EK, Konstantaki J, Beasley TM, Allison DB, Czucza C, Simmons HA, Kemnitz JW, Richard W (2009) Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325, 201–204.

Coolican SA, Samuel DS, Evton DZ, Mc Wade FJ, Florini JR (1997) The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J. Biol. Chem. 272, 6653–6662.

Coppe JP, Pati CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez P-Y, Campisi J (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853–2868.

Coppe P, Migliore L (2010) DNA repair in premature aging disorders and neurodegeneration. Curr. Aging Sci. 3, 18–39.

Courtois S, Verhaegh G, North S, Luciani M-G, Lassus P, Hibner U, Oren M, Hainaut P, van Deursen JM (2014) The role of senescent cells in ageing. Tumor Biol. 35, 5785–5795.

Chabot B (2001) p53 is an ancient tumor suppressor gene. Nat. Rev. Mol. Cell Biol. 2, 309–316.

De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Fumagalli S, Barenboim E, Cho R, Konner H, Schauer A, Bäumer L, Hainaut P (2002) Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct functional properties. J. Cell Biol. 158, 907–918.

Daguenet E, Dujardin G, Valcarcel J (2015) The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches. EMBO Rep. 16, 1640–1655.

Deak E, Szabó A, Rózsa B, Eperjesi F, Süll J, Molnár T, Antal G (2013) Noncoding RNA expression patterns in human neuroblastoma cell lines. J. Cell. Biochem. 114, 446–456.

Díaz-Hernández J, Sebastián-Serrano Á, Gómez-Villafuertes R, Díaz-Hernández M, Miras-Portugal MT (2015) Age-related nuclear translocation of P2X6 subunit modifies splicing activity interacting with splicing factor 3A. PLoS ONE 10, e0123121.

Díez J, del Río G (2006) Intracellular communication of TGFβ signaling in vascular development and disease. Nat. Rev. Mol. Cell Biol. 7, 553–564.

Díez J, del Río G (2006) Intracellular communication of TGFβ signaling in vascular development and disease. Nat. Rev. Mol. Cell Biol. 7, 553–564.

Díez J, del Río G (2006) Intracellular communication of TGFβ signaling in vascular development and disease. Nat. Rev. Mol. Cell Biol. 7, 553–564.
Alternative splicing in senescence and aging, M. Deschênes and B. Chabot

Hartl R, Schraml E, Cirolo A, Megalou E, Weiskopf D, Lau P, Heerens G, Breitenbach M, Grubeck-Loebenstein B, Herker E, Fahrenkrog B, Frohlich K-U, Stover F, Tavara-nakis N, Minois N, Kroemer G, Marquart M (2009) Induction of autophagy by spermide promotes longevity. Nat. Cell Biol. 11, 1305–1314.

Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Fisette J-F, Montagna DR, Mihailescu M-R, Wolfe MS (2012) A G-rich element are endogenous regulators of mammalian physiology. Curr. Opin. Cell Biol. 20, 303–309.

Feng X, Hara Y, Riabowol KT (2002) Different HATs of the ING1 gene family. Trends Cell Biol. 12, 532–538.

Fujita K, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavaramu S, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP, Sinclair DA (2008) The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. M. V. Blagosklonny, ed. PLoS ONE 3, e2020.

Trends Cell Biol., 574.

Jones N, Kabala N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J, Kaeberlein M, McVey M, Guarente L (1999) Correlative memory deficits, Abeta amyloidosis, and amyloid plaques in transgenic mice. Science 284, 197–200.

K.deb Sk J, Ouedraogo F, Hara Y, Riabowol KT (2002) Different HATs of the ING1 gene family. Trends Cell Biol. 12, 532–538.

Fujita K, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavaramu S, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP, Sinclair DA (2008) The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. M. V. Blagosklonny, ed. PLoS ONE 3, e2020.

Hajjy M, Quevedo HC, Tiwari S, Sukhanov S, Shai S-Y, Anwar A, Delafontaine P (2014) Interaction between insulin-like growth factor-I and atherosclerosis and vascular aging. Front. Horm. Res. 43, 107–124.

Hirsch AJ, Jodelka FM, Chang JL, Bratman D, Bruno MA, Briggs CA, James BD, Stutzmann GE, Bennett DA, Miller SA, Rigo F, Marr RA, Hastings MJ (2016) Correction of cellular phenotypes of Hutchinson-Gilford progeria syndrome by RNA interference and through effects on p53. Hum. Mol. Genet. 15, 356–366.

Howard JD, Sanford JR (2015) The RNAassae family: SR proteins as multifaceted regulators of gene expression. Wiley Interdiscip. Rev. RNA 6, 93–110.

Hsiao K, Chapman P, Nilsen G, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta amyloidosis, and amyloid plaques in transgenic mice. Science 284, 197–200.

Huang S, Chen L, Libina N, Janes J, Martin GM, Kubisch C, Oshima J (2011) Coronary artery disease in a Werner syndrome-like form of progeria characterized by low levels of progerin, a splice variant of lamin A. M. V. Blagosklonny, ed. PLoS ONE 3, e2020.

Holly AC, Melzer D, Pilling LC, Fellows AC, Tanaka T, Ferrucci L, Harries LW (2013) Changes in splicing factor expression are associated with advancing age in man. Mech. Ageing Dev. 134, 356–366.

Howell JM, Sanford JR (2015) The RNAassae family: SR proteins as multifaceted regulators of gene expression. Wiley Interdiscip. Rev. RNA 6, 93–110.

Hisama FM, Lessel D, Leistritz D, Friedrich K, McBride KL, Pastore MT, Gottesman GS, Saha S, Martin GM, Kubisch C, Oshima J (2011) Coronary artery disease in a Werner syndrome-like form of progeria characterized by low levels of progerin, a splice variant of lamin A. M. V. Blagosklonny, ed. PLoS ONE 3, e2020.

Hochleitner R, Schraml E, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavaramu S, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP, Sinclair DA (2008) The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. M. V. Blagosklonny, ed. PLoS ONE 3, e2020.

Kfairkho F, Blandino M, Goldspink G, Harridge SDR (2003) Expression of premature senescence marker and tumor suppressor genes. J. Physiol. 554, 135–147.

Kiser C, Saar K, Hubner N, Croce CM, Kaelberlein M, McVey M, Guarente L (1999) The SR2/S3 complex and SR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 13, 2570–2580.

Kijima T, Weber JD, Zambetti G, Zindy F, Rousset MF, Sherr CJ (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95, 8229–8237.

Kandalepas PC, Vassar R (2014) The normal and pathologic roles of the tumor suppressor p53. J. Radiat. Res. 55, 115–125.

Jeyapalan JC, Ferreira M, Sedivy JM, Herrig U (2007) Accumulation of senescent cells in mitotic tissue of aging primates. Mech. Ageing Dev. 128, 36–44.

Jin Y, Yang T, Zhang P (2011) New insights into RNA secondary structure in the alternative splicing of pre-mRNAs. RNA 18, 450–457.

Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J (2009) Sir2 is an inhibitor of proliferation and tumor formation in colon cancer. J. Biol. Chem. 284, 18210–18217.

Kim H-J, Oh G-S, Choe S-K, Kwak TH, Park R, So H-S (2014) NAD(+) metabolism in age-related hearing loss. Aging Dis. 5, 150–157.

Kirkwood TBL (2005) Understanding the odd science of aging. PLoS Biol. 3, 148–153.

Kiyokawa H, Gudkov AV (2006) Targeted disruption of the mouse lng1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas. Oncogene 25, 857–866.

Kim C-H, Oh G-S, Choe S-K, Kwak TH, Park R, So H-S (2014) NAD(+) metabolism in age-related hearing loss. Aging Dis. 5, 150–157.
Owino V, Yang SY, Goldspink G (2001) Age-related loss of skeletal muscle function and the inability to express the autocrine form of insulin-like growth factor-1 (IGF1) in response to mechanical overload. FEBS Lett. 505, 259–263.

Pan Q, Shi O, Lee LJ, Frey BJ, Blencowe BJ (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40, 1413–1415.

Panasyuk G, Némazanyi I, Zhvolyoup A, Filonenko V, Davies D, Robson M, Pedley RB, Waterfield M, Gout I (2009) mTOR splicing isoform promotes cell proliferation and tumorigenesis. J. Biol. Chem. 284, 30807–30814.

Panda AC, Abdelmohsen K, Gorospe M (2017a) SASP regulation by noncoding RNA splicing. Aging Cell 16, 900–909.

Panda AC, Abdelmohsen K, Gorospe M (2017b) Identification of senescence-associated circular RNAs (SAC-RNAs) reveals senescence suppressor CircPVT1. Nucleic Acids Res. 45, 4021–4035.

Parrinello S, Coppe JP, Kortolica A, Campisi J (2005) Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J. Cell Sci. 118, 485–496.

Pehar M, O’Riordan KJ, Burns-Cusato M, Andrzejewski ME, del Alcazar CG, Burger RS, Martindale JL, Munk R, Yang X, Panda AC, Abdelmohsen K, Gorospe M (2017b) Identification of senescence-associated circular RNAs (SAC-RNAs) reveals senescence suppressor CircPVT1. Nucleic Acids Res. 45, 4021–4035.

Perrino F, Picard C, Ferrando AA, Cordon-Cardo C (2007) Amplification of the insulin-like growth factor I (IGF-I) receptor is associated with poor outcome and a new growth factor I (IGF-I) driven mechanism of p53 loss in breast cancer. Cancer Cell 12, 267–278.

Rodríguez SA, Grochova D, McKenna T, Borate B, Trivedi NS, Erdos MR, Eriksson M (2016) Global genome splicing analysis reveals an increased number of alternatively spliced genes with age-related changes. Aging Cell 15, 267–279.

Rufini A, Tucci P, Celardo I, Melino G (2013) Senescence and aging: the critical roles of p53. Oncogene 32, 5129–5143.

Sage J, Miller AL, Pérez-Mancera PA, Wysocki JM, Jacks T (2003) Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424, 223–228.

Salminen A, Kauppinen A, Suuronen T, Kaarniranta K (2008) SIRT1 longevity factor suppresses NF-κB-driven immune responses: regulation of aging via NF-κB acetylation? BioEssays 30, 939–942.

Salmont M, Distel T (2016) Small molecule modulators of pre-mRNA splicing in cancer therapy. Trends Mol. Med. 22, 28–37.

Sánchez-Jiménez C, Ludeña MD, Izquierdo JM (2015) T-cell intracellular antigens function as tumor suppressor genes. Cell Death Dis. 6, e1669.

Scaffidi P, Misteli T (2006) Lamin A-dependent nuclear defects in human aging. Science 312, 1059–1063.

Schmid S, Essmann F, Cirstea IC, Kuck F, Thakur HC, Singh M, Kletke A, Jänike RU, Wiek C, Henabergen H, Ahmadian MR, Schulze-Osthoff K, Nürnberg B, Piekorz RP (2010) The centrosome and mitotic spindle apparatus in cancer and senescence. Cell Cycle 9, 4489–4473.

Schwerk C, Schulze-Osthoff K (2005) Regulation of apoptosis by alternative pre-mRNA splicing. Mol. Cell 19, 1–13.

Scott M, Bonnefin P, Vieyra D, Boisvert FM, Young D, Bazett-Jones DP, Riabowol K (2001) UV-induced binding of ING1 to PCNA regulates the induction of apoptosis. J. Cell Sci. 114, 3455–3462.

Scotti MM, Swanson MS (2015) RNA mis-splicing in disease. Nat. Rev. Genet. 17, 19–32.

Shukla S, Saaki T, Naier B (2005) DeltaNP53 or p44: priming the p53 pump. Int. J. Biochem. Cell Biol. 37, 913–919.

Serra MB, Ferrucci L, Bartali B, Urpi-Sarda M, Zamora-Ros R, Sun K, Cherubini A, Bandinelli S, Andres-Lacueva C (2014) Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern. Med. 174, 1077.

Shukla S, Kavak E, Gregory M, Imashimizu M, Shutinoski B, Kashlev M, Sjöberg E, C19, 973, 979.

This work was supported by the Anatomical Society and John Wiley & Sons Ltd.
Tollervey JR, Wang Z, Varela I, Cadiz-Tang Y, Horikawa I, Ajiro M, Robles AI, Fujita K, Mondal AM, Stauffer JK, Zheng Z-Vieyra D, Toyama T, Hara Y, Boland D, Johnston R, Riabowol K (2002b) ING1. PLoS Genet. 5, e1000776.

Stavropoulou A, Halapas A, Sourla A, Philippou A, Papageorgiou E, Papalois A, Storer M, Mas A, Robert-Moreno A, Pecoraro M, Ortells MC, Di Giacomo V, Yosef N, Pastyryeva S, Vielmo F-M, Cheema P, Pastyryeva S, Bonnefin P, Boisvert F-M, Scott M, Bonnefin P, Feng X, Colina A, Young D, Forsyth P, Garkavtsev I, Kobayashi S, Riabowol K (1999) Suppression of ING1. Nature 400, 307–310.

Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408, 307–310.

Von Zglinicki T (2002) Oxidative stress shortens telomeres. Trends Biochem. Sci. 27, 339–344.

Wang E (1995) Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. Cancer Res. 55, 2284–2292.

Wang ET, Sandberg R, Luo S, Khrebttukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB (2008) Alternative isoform regulation in human tissue transcriptomes. Nature 455, 470–476.

Wang J, Geiger H, Rudolph KL (2011a) Immunogenicity induced by hematopoietic stem cell aging. Curr. Opin. Immunol. 23, 532–536.

Wang X, Zeng L, Wang J, Chau JFL, Lai KP, Jia D, Poonepalli A, Hande MP, Liu H, He G, He L, Li B (2011b) A positive role for c-Abl in Atm and Atr activation in DNA damage response. Cell Death Differ. 18, 5–15.

Werner H, Kamilii E, Rauscher FJ, Leboith D (1996) Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl Acad. Sci. USA 93, 8318–8323.

Whitaker R, Faulkner S, Miyokawa R, Burhenn L, Henrikson M, Wood JG, Helfand SL (2013) Increased expression of Droso phila sir2 extends life span in a dosage-dependent manner. Aging 5, 682–691.

Wood AM, Danielsen JMR, Lucas CA, Rice EL, Scalzo D, Shimi T, Goldman RD, Smith ED, Le Beau MM, Kosak ST (2014) TF2B and lamin A/C interact to facilitate the functional organization of chromosome ends. Nat. Commun. 5, 5467.

Yang SY, Goldspink G (2002) Different roles of the IFG-1 Ec peptide (MFG) and mature IFG-I in myoblast proliferation and differentiation. FEBS Lett. 522, 156–160.

Yeow GW, Coufal NG, Liang TY, Peng GE, Fu X-D, Gage FH (2009) An RNA code for the FOX2 splicing regulator revealed by mapping RNA-protein interactions in stem cells. Nat. Struct. Mol. Biol. 16, 130–137.

Yu C-Y, Theusch E, Lo K, Mangravite LM, Naidoo D, Kutlova M, Medina MW (2014) HNRNPA1 regulates HMGCGR alternative splicing and modulates cellular cholesterol metabolism. Hum. Mol. Genet. 23, 319–332.

Zhang Z, Lotti F, Dittmar K, Younis I, Wan L, Kasim M, Dreyfuss G (2008) SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 133, 585–600.

Zhao W, Zhao J, Hou M, Wang Y, Zhang Y, Zhao X, Zhang C, Guo D (2014) HuR differentially regulates the FOX2 splicing regulator revealed by mapping RNA-protein interactions in stem cells. Mol. Neurodegener. 6, 15.

Zheng H, Koo EH (2011) Biology and pathophysiology of the amyloid precursor protein. Mol. Neurodegener. 6, 27.

Zhu Y, Tchkonia T, Pirtskhalava T, Gower AC, Ding H, Giordadze N, Palmer AK, Ikeno Y, Hubbard GB, Leinburg M, O’Hara SP, LaRusso NF, Miller JD, Roos CM, Verzosa GC, LéBrasseur NK, Wren JD, Farr JN, Khosia S, Stout MB, McGowan SJ, Fuhrmann-Stroissnig H, Gorkur AU, Zhao J, Colangelo D, Dorrnorsoro A, Ling YY, Barchyouth AS, Navarro DC, Sano T, Robbins PD, Niederhofer LJ, Kirkland JL (2015) The Achilles’ heel of senescent cells: from transcription to senolytic drugs. Aging Cell 14, 644–658.

Zohar O, Pick CG, Cavallaro S, Chapman J, Katzav A, Milman A, Alkon DL (2005) Age-dependent differential expression of BACE splice variants in brain regions of tg2576 mice. Neurobiol. Aging 26, 1167–1175.

© 2017 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.

Alternative splicing in senescence and aging, M. Deschênes and B. Chabot